FCF Life Science Research

FCF engages in research on recent financing trends in the Life Science sector, i.e. biotechnology, pharma and med-tech. FCF primarily focuses on the latest activities in the equity capital markets: Venture Capital, Initial Public Offerings (IPO) and Equity Valuations. The findings are regularly published in

FCF LIFE SCIENCE MONITOR

The FCF Life Science Monitor comprises of listed small- and midcap companies, headquartered in Europe, from the biotechnology, pharma and med-tech sectors. The report is a derivative of the FCF Valuation Monitor, adjusted to valuation and performance metrics suited for the Life Science sector.

The analysis focuses on

  • Performance and Valuation Analysis
  • Break-even Analysis
  • Share Price Potential Analysis
  • Shareholder Analysis
  • Liquidity Analysis

FCF LIFE SCIENCE IPO REPORT

The FCF Life Science IPO Report examines recent IPO trends in the Life Science sector, with a strong focus on the comparison of European and US characteristics

  • Size Segment Analysis
  • Sub-sector Analysis
  • Investor Analysis
  • Liquidity Analysis
  • Share Pricing / Trading Analysis
  • Underwriter Analysis

FCF LIFE SCIENCE VC REPORT

The FCF Life Science VC Report analyses the latest VC funding activities in the Life Science sector. The report provides a detailed investigation on funding dynamics in Europe and the US

  • Sub-sector Analysis
  • Deal Volume Analysis
  • Investor Analysis
  • Cross-Border Analysis
  • Fund Raising Analysis

LIFE SCIENCE PUBLICATIONS

RECENT LIFE SCIENCE TRANSACTIONS

AMW GmbH

EIB Debt Facility
November 2017
€ 25 million
numares transaction

numares AG

Capital Increase
November 2017
€ 11 million
[confidential]

Leading Healthcare Equipment Provider

EIB Debt Facility
August 2017
€ 35 million

Biofrontera AG

EIB Debt Facility
May 2017
€ 20 million